Shandong Xinhua Pharmaceutical announced on the evening of September 3 that the company recently received the National Medical Products Administration's approval and issuance of the supplementary application approval notice for the transfer of the holder of the marketing authorization for the injection of ketoprofen. The company has become the holder of the marketing authorization for this pharmaceutical.
新华制药：获得己酮可可碱注射液药品补充申请批准通知书
Shandong Xinhua Pharmaceutical: Obtained the Notice of Approval for Supplementary Application of Ketamine Hydrochloride Injection
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.